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Background:   The HPDPCC was introduced in our clinical 
practice in 2005, and it has some specific clinical 
recommendations. We use Octaplex® mostly to revert 
coagulation parameters in patients whose satus require 
their quick conversion, mainly to reverse oral 
anticoagulation. We initially started using Octaplex® in 
lower doses than the recommended by the drug leaflet, 
trying to find an optimal dose, aiming to avoid side effects. 
Aims:   Our goals are to share our experience using 
Octaplex® in clinical practice, demonstrating that we can 
obtain rapid results with minimal dose, without adverse 
events.  
  
Methods:   We only included in this study patients who 
have done Octaplex® (1 unit = 20 ml) and have results of 
measurement of their International Normalized Ratio (INR) 
before and after the infusion of prothrombin complex 
concentrate. The INR was determined using the fully 
automated hemostasis analyser BCS® XP System (Siemens) 
and the reagent Innovin® (Dade Behring).  The period of 
the study was 2005-2010, and included 87 patients with 
different diseases. The INR results upper than 10 were 
counted like 10 because the laboratory doesn’t quantify 
values higher than this.  
Results:    The patients were 64 men and 23 women, with 
ages ranged between 18 and 85 years old, average 66.5 
years old. 53 were under treatment with oral 
anticoagulants (OAC), 22 with liver impairment (LI), and 12 
with other pathologies (OP). The INR before treatment 
varied from 10 (maximal value) to 1.4 (minimal value), the 
average values were 6.72 to the patients under OAC, 2.15 
to the patients with LI and 3.39 to the patients with OP. 
After treatment the average values were 2.0 to the OAC, 
1.84 to the LI and 1.76 to the OP. After treatment the 
maximal value of the INR was 6.9 and the minimal 0.9. The 
average number of units used to revert the patients clinical 
status were for OAC 1.62 (in an average of 1.04 number of 
intakes), for LI 2 units (1 intake) and for OP 2.75 units (1.42 
intakes). We didn’t find any adverse post-administration 
events.  
  
Summary/conclusions:   We found better results in the administration of Octaplex® in patients doing OAC, where the 1.62 
units (in 1.04 intakes) lowered the INR average from 6.72 to 2.0. The other results (in LI and OP) were less expressive but still 
encouraging towards recommending it. The dose used to resolve our clinical cases were much lower than the recommended 
in the drug leaflet. We didn’t find any adverse events in this dose. The clinical practice feedback suggests a quicker INR 
conversion comparing to fresh frozen plasma.  
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